Approximately half of patients with axial spondyloarthritis (axSpA) and inflammatory bowel disease (IBD) achieved clinical remission at the 12-month mark after initiating tumor necrosis factor inhibitor (TNF) therapy, according to data presented at Digestive Disease Week (DDW) 2023.1 Adalimumab treatment and a shorter disease duration may be linked with higher odds of clinical remission in patients with axSpA. However, larger studies are needed to verify these results in addition to investigate alternative therapies for this patient population. “The disease activity of axSpA among patients with IBD who start anti-TNF agents is poorly understood,” wrote Rahul S Dalal, MD, Gastroenterology, Brigham and Women's Hospital, and colleagues. “We sought to identify clinical factors associated with remission of axSpA after initiation of anti-TNF agents among patients with Crohn’s disease (CD) and ulcerative colitis (UC).” Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then ...

read more